



## Synonym

B7-H6,NCR3LG1,B7 Homolog 6

## Source

Human B7-H6 Protein, His Tag(B76-H52H8) is expressed from human 293 cells (HEK293). It contains AA Asp 25 - Ser 262 (Accession # [Q68D85-1](#)).

Predicted N-terminus: Asp 25

## Molecular Characterization

B7-H6(Asp 25 - Ser 262)  
Q68D85-1 Poly-his

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 28.6 kDa. The protein migrates as 38-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

## Endotoxin

Less than 1.0 EU per µg by the LAL method.

## Purity

>90% as determined by SDS-PAGE.

## Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

## Reconstitution

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

## Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

## SDS-PAGE




Human B7-H6 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

## Bioactivity-ELISA

Discounts, Gifts,  
and more!





Immobilized Human NKp30, Fc Tag (Cat. No. NC3-H5259) at 10  $\mu$ g/mL (100  $\mu$ L/well) can bind Human B7-H6 Protein, His Tag (Cat. No. B76-H52H8) with a linear range of 0.016-0.25  $\mu$ g/mL (QC tested).

## Background

The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome.

Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.

## Clinical and Translational Updates

Discounts, Gifts,  
and more!

